12:00 AM
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DermaPACE: Phase III start

This quarter, Sanuwave will begin a double-blind, U.S. Phase III trial to evaluate dermaPACE in combination with standard of care in >=90 patients with diabetic foot ulcers. Patients will receive 4 treatments with dermaPACE or sham during the first 2 weeks and up to 4 additional treatments during weeks 4-10. Sanuwave plans to submit a PMA...

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >